Citations

Clear

4610 citation(s) found for "Lu, Brian".

Epidermal growth factor receptor regulates Beclin-1 in hyperoxic acute lung injury
Harris, Zachary M , Korde, Asawari, Manning, Edward P., Stanley, Gail, Shin, Yosep, Mitchell, Kennedy, Schulenburg, Alexa von der, Sun, Ying, Hu, Buqu , Shin, Hyeon Jun , Joerns, John, Clark, Brian, Placek, Lindsey , Moldobaeva, Aigul, Sharma, Lokesh , Sauler, Maor, Rajagopalan, Govindarajan, Zhang, Xuchen, Wang, He, Ghaedi, Mahboobe, Koff, Jonathan L, Zhang, Xuchen , Manning, Edward P , Korde, Asawari , Khoury, Johad , Sun, Ying S., Joerns, John , Clark, Brian J., Unutmaz, Derya , Sauler, Maor , Ghaedi, Mahboobe , Kang, Min‐Jong , Koff, Jonathan L.

Mayo Clinic

BMJ Open Respiratory Research | January 27, 2026 | Volume: 13 | Issue: 1 | Pages: e003323

10.1136/bmjresp-2025-003323 | PMID 41592865 Get It

Background While delivery of supplemental oxygen is a life-saving therapy, exposure to high oxygen, called hyperoxia, leads to increased intensive care unit mortality. Hyperoxia induces oxidant-mediated acute lung injury (ALI) and pulmonary cell death, called hyperoxic ALI (HALI). Elucidating molecular mechanisms in HALI could identify therapeutic targets in ALI. Methods In the current study, we examined in vivo effects of HALI on Beclin-1 (BCN1), which regulates autophagy, and modulation of BCN1 by epidermal growth factor receptor (EGFR). Effects of HALI on BCN1 and autophagy were examined in mice with genetically decreased EGFR (EGFR Wa5/+ ). Wildtype (WT) and EGFR Wa5/+ mice were exposed to 100% oxygen for 24–72 hours along with normoxia controls (eight groups; n=4–6/group), and analysis of pulmonary BCN1 and autophagy was completed. Results In WT, HALI led to increased BCN1 (59% increased total BCN1/β-Actin; p<0.01) in lung and alveolar epithelium (484% increased H-score; p<0.001). HALI led to decreased microtubule-associated protein 1B-light chain (LC3B)-II/-I ratios (43% decrease; p<0.05) and increased p62 (93% increase; p<0.05), suggesting reduced autophagic flux. In human alveolar type-II cells derived from induced pluripotent stem cells (AT2s iPSC ), HALI caused increased LDH release (130% increase; p<0.0001) and decreased LC3B-II/-I ratios (32% decrease; p<0.05). We previously showed that EGFR Wa5/+ mice are protected in HALI. In the current study, EGFR Wa5/+ mice showed increased pulmonary BCN1 (122% increase; p<0.05), reduced phosphorylated-(p-)/total BCN1 (47% decrease; p<0.05) and decreased LC3B-II/-I ratios (70% decrease; p<0.01) in HALI compared with WT. In addition, wortmannin (1 mg/kg), which decreases BCN1-mediated autophagy, increased mortality in HALI compared with vehicle control (n=10/group; 18% decreased hours survived; p<0.001). Conclusions These data delineate a novel cell death pathway in HALI involving BCN1 and EGFR with therapeutic potential.
Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis
Lacy, Brian E., Shin, Andrea S., Cangemi, David J. , Yang, Yang, Zhao, Suling , Rosenbaum, David P. , Lacy, Brian E , Lacy, Brian E. , Shin, Andrea

Mayo Clinic

Therapeutic Advances in Gastroenterology | January 25, 2026 | Volume: 19 | Issue: No issue available | Pages: No page available

10.1177/17562848251414831 | PMID 41601848 Get It

Background: In patients with irritable bowel syndrome with constipation (IBS-C), rapid, sustained relief from constipation and abdominal symptoms, such as pain, discomfort, and bloating, can improve quality of life. Objective: This post hoc analysis evaluates the time to constipation and abdominal symptom relief achieved with tenapanor. Design: Post hoc analysis of data pooled from three randomized placebo-controlled studies (phase IIb, T3MPO-1, and T3MPO-2) of tenapanor 50 mg twice daily in patients with IBS-C. Methods: The time to first response for complete spontaneous bowel movement (CSBM) frequency, abdominal pain, discomfort, bloating, and 3-item abdominal score (AS3) were assessed. The AS3 was derived as the average of the weekly scores for abdominal pain, discomfort, and bloating. Cumulative incidences of response over time were estimated using the Kaplan–Meier method. A Cox proportional hazards model was used to assess the effect of baseline and demographic characteristics on the time to first response. Results: Among 1372 patients with IBS-C (684 tenapanor; 688 placebo), median time to first CSBM response was 2 weeks, and median time to abdominal pain, discomfort, bloating, or AS3 response was 4–5 weeks in those treated with tenapanor, with 67.8%–76.7% achieving first response in CSBM frequency and abdominal symptoms by week 12. These time frames were shorter than those observed with the placebo (4 weeks for CSBM and 6–8 weeks for pain, discomfort, bloating, and AS3), of whom 59.1%–69.4% achieved the first response in CSBM and abdominal symptoms by week 12. Higher weekly response rates were observed with tenapanor than with placebo for all endpoints in each week of the 12-week treatment period. Conclusion: This novel post hoc analysis demonstrates that, compared with placebo, tenapanor reduces the time to first response in CSBM frequency and abdominal symptoms and consistently increases the weekly response rate during 12 weeks of treatment. Trial registration: NCT01923428; NCT02621892; NCT02686138.
Disparities across the pediatric epilepsy surgery journey: Referral, recommendation, and completion from a national consortium
Berl, Madison M. , Wagner, Janelle L. , Caraway, Avery Robert, Loblein, Hayley , Novotny, Edward J. , Patrick, Kristina E. , Ostendorf, Adam P. , Alexander, Allyson , Eschbach, Krista , Depositario‐Cabacar, Dewi F., Vu, Thuy‐Anh , Karia, Samir R., Romanowski, Erin Fedak , Bolton, Jeffrey , Ailion, Alyssa , Tatachar, Priyamvada, Pichon, Pilar, Shrey, Daniel W. , Singh, Rani K., Lin, Jenny, Koop, Jennifer I. , Gonzalez‐Giraldo, Ernesto, Auguste, Kurtis I. , Bernardo, Danilo , Ciliberto, Michael A. , Reddy, Shilpa B. , Ganesh, Abhinaya, Arredondo, Kristen H. , Nangia, Srishti, Samanta, Debopam, Marashly, Ahmad , Armstrong, Dallas , Perry, M. Scott, Workgroup, the PERC Surgery, Caraway, Avery R. , Wagner, Janelle , Caraway, Avery Robert , Patrick, Kristina E , Alexander, Allyson L , Eschbach, Krista , Depositario Cabacar, Dewi Frances , Oluigbo, Chima O , Karia, Samir , Karakas, Cemal , Wong-Kisiel, Lily C. , Fedak Romanowski, Erin , McNamara, Nancy A , Bolton, Jeffrey Brian , Ailion, Alyssa , Tatachar, Priyamvada , Pichon, Pilar D , Shrey, Daniel W , Coryell, Jason , Koop, Jennifer I , Gonzalez-Giraldo, Ernesto , Auguste, Kurtis I , Bernardo, Danilo , Ciliberto, Michael A , Reddy, Shilpa B , Ganesh, Abhinaya , Arredondo, Kristen H , Grinspan, Zachary , Nangia, Srishti , Samanta, Debopam , Armstrong, Dallas Michael , Perry, Michael Scott , Berl, Madison , Novotny, Edward J , Loblein, Hayley, Depositario‐Cabacar, Dewi, Oluigbo, Chima , Karia, Samir , Karakas, Cemal , Wong‐Kisiel, Lily C. , McNamara, Nancy , Tatachar, Priyamvada , Coryell, Jason , Gonzalez‐Giraldo, Ernesto , Grinspan, Zachary M. , Samanta, Debopam

Mayo Clinic

Epilepsia | January 24, 2026 | Volume: 67 | Issue: 4 | Pages: 1601-1613

10.1002/epi.70060 | PMID 41579031 Get It

Abstract Objective Despite being safe and effective, surgery for pediatric epilepsy is underutilized. Social determinants of health (SDoH) are important to consider when examining this treatment gap. This study examined the potential systemic inequities at three different stages in the journey toward epilepsy surgery across the Pediatric Epilepsy Research Consortium (PERC). Methods Any youth in the PERC prospective surgery database (≤18 years) was eligible and included if sociodemographic factors were also available. We examined if there were differences in disparity factors in: (1) referral to Phase I evaluation, (2) offering of surgery, and (3) completion of surgery. Results Of 1309 patients, the majority were male (53%, p = .04), White (82.2%, p < .001), not Hispanic or Latino (84.3%, p < .001), and privately insured (56.3%, p < .001). Of the youth who were offered surgical treatment ( n = 1103, 84.3%), there were no significant differences in race/ethnicity or sex. Those with a structural lesion were more likely to be offered surgery, and historically marginalized youth were more likely to have a lesion. Of patients who completed surgery ( n = 927, 84.0%), White patients were 1.88 times (95% confidence interval [CI]: 1.14–3.04) more likely than Black patients to complete surgery ( p = .01). Significance Youth who began surgery evaluation are not representative of the demographics of those with epilepsy in the United States, with greater representation of White, non‐Hispanic male individuals. In addition, youth who began surgery evaluation disproportionally have private insurance. At the next stage of offering surgery, there were no differences based on SDoH. However, there is evidence that underrepresented youth that were magnetic resonance negative were less likely to be referred for surgical workup and that Black youth were less likely to undergo surgery. Therefore, efforts to provide equitable opportunity for all youth with refractory epilepsy should be concentrated at the referral for surgery evaluation point of care; however, additional efforts are also needed at later stages.
Assessing Braak stage agreement between four Tau PET tracers
Rocha, Andreia, Bellaver, Bruna, Soares, Carolina, Ferreira, Pamela C.L., Madeiros, Marina Scop, Povala, Guilherme, Amaral, Lívia , Lussier, Firoza Z, Mroué, Rayan, Masdeu, Joseph C., Tudorascu, Dana L, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Rocha, Andreia, Bellaver, Bruna , Soares, Carolina , Ferreira, Pâmela C.L. , Ruppert, Emma Patrice , Madeiros, Marina Scop, Povala, Guilherme , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Rodrigues, Matheus Scarpatto , Masdeu, Joseph C , Tudorascu, Dana , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 22, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107635 | PMID 41570193 Get It

Abstract Background The Alzheimer's disease (AD) Braak staging is a key framework for classifying tau pathology progression in AD based on histopathological post‐mortem brain examinations. However, adapting it to PET imaging can be challenging due to differences in tracer uptake patterns and binding properties, which affect sensitivity, specificity, and regional staging. This study compares Braak staging across four tau PET tracers: Flortaucipir, MK6240, PI2620, and RO948. Methods We assessed 90 participants across the AD spectrum (46 CU, 31 MCI, 13 dementia; mean age 66.1 ± 7.8) using Aβ PET and four tau PET tracers: (Flortaucipir, MK6240, PI2620, and RO948). Braak positivity was defined based on Aβ− CU individuals (mean +2.5 SD, SUVR). To evaluate systematic bias and agreement between tracers, we computed pairwise differences at corresponding Braak stage estimates and applied the Bland‐Altman method to assess mean bias and limits of agreement. Additionally, Tau PET Braak region trajectories were modeled as functions of Aβ burden (Centiloid scale) using the Lowess method. Results Braak stage trajectories as a function of Aβ differ depending on the tracer and the sequential order of abnormality is highly variable. For instance, while for MK6240, RO948 and PI2620, Braak I is the first region to became abnormal, for Flortaucipir the earliest region to became abnormal is Braak IV (Figure 1). This variable pattern of abnormality impacts in the concordance of Braak staging between tracers with the highest Braak staging agreement resulting in concordance levels of approximately 70%. The highest levels of agreement between tracers usually happen at Braak 0 or Braak IV‐V, with intermediate stages showing very low concordance (Figure 2). The Bland‐Altman analysis identified wide limits of agreement, suggesting high variability and high tracer‐specific differences (Figure 3). On the other hand, it also identified that mean differences between tracers were small, indicating minimal systematic bias. Conclusion These preliminary findings reveal discrepancies in Braak staging when comparing Flortaucipir, MK6240, PI2620 and RO948. These findings suggest that while the tracers provide comparable stages on average, they may not be fully interchangeable in individual cases.
Long-term tumor control after Gamma Knife radiosurgery for sporadic vestibular schwannoma
Marinelli, John P. , Daher, Ghazal S. , Khandalavala, Karl R. , Babajanian, Eric E. , Dornhoffer, James R. , Lohse, Christine M., Pollock, Bruce E., Brown, Paul D., Gompel, Jamie J. Van, Celda, María Peris, Neff, Brian A., Driscoll, Colin L. W., Carlson, Matthew L. , Link, Michael J., Lohse, Christine M. , Pollock, Bruce E. , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 4 | Pages: 965-971

10.3171/2025.8.jns25829 | PMID 41569741 Get It

OBJECTIVE The objective of this study was to describe the long-term efficacy of single-fraction stereotactic radiosurgery (SRS) for the primary treatment of sporadic vestibular schwannoma. METHODS Adult (≥ 18 years of age) patients with sporadic vestibular schwannoma who underwent SRS from 2000 through 2022 were included. RESULTS A total of 749 patients met inclusion criteria, the majority (n = 566, 76%) of whom had tumors extending into the cerebellopontine angle at SRS. The median patient age at SRS was 62 years, half (50%) of the patients were women, and 744 (99%) exhibited House-Brackmann grade I facial nerve function at SRS. A total of 42 patients experienced radiosurgical failure and underwent salvage treatment; the median duration of follow-up for the patients who did not undergo salvage treatment was 7.0 years. Overall tumor control rates (95% CI, number still at risk) at 1, 3, 5, 10, and 15 years after SRS were 100% (100%–100%, 718), 98% (97%–99%, 589), 96% (94%–97%, 464), 92% (90%–95%, 258), and 91% (89%–94%, 125), respectively. Patient age (hazard ratio [HR] for a 10-year increase of 0.92, 95% CI 0.71–1.19; p = 0.5), presence of a macrocystic tumor (HR 0.59, 95% CI 0.14–2.46; p = 0.5), and treated tumor volume (HR for a 1-cm 3 increase of 1.02, 95% CI 0.88–1.18; p = 0.8) were not significantly associated with the risk of salvage. Three distinct post-SRS tumor behavior patterns were observed, with 13% of patients demonstrating tumor pseudoprogression, all but 4 of whom demonstrated pseudoprogression by year 5 post-SRS. CONCLUSIONS SRS demonstrates durable tumor control through 15 years of follow-up in most patients (91%); however, a minority are found to still experience SRS failure even beyond 10 years of surveillance. Although occurring in only a minority of patients, tumor pseudoprogression can be evident out to 5 years or longer post-SRS.
Defining clinically significant tumor size in sporadic vestibular schwannoma to inform timing of radiosurgery during wait-and-scan management: further evidence supporting size threshold surveillance
Carlson, Matthew L. , Marinelli, John P. , Babajanian, Eric E. , Daher, Ghazal S. , Dornhoffer, James R. , Khandalavala, Karl R. , Lohse, Christine M., Gompel, Jamie J. Van, Celda, María Peris, Neff, Brian A., Driscoll, Colin L. W., Link, Michael J., Lohse, Christine M. , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 4 | Pages: 955-964

10.3171/2025.8.jns25830 | PMID 41569717 Get It

OBJECTIVE Wait-and-scan surveillance is now commonly employed for initial management of small- and medium-sized vestibular schwannomas. Although small differences in tumor size are unlikely to impact outcomes significantly, treatment with either radiosurgery or microsurgery is usually recommended following radiological detection of tumor growth. The objective of the current study was to identify potential inflection points in vestibular schwannoma tumor size, where the risks of treatment with single-fraction stereotactic radiosurgery (SRS) accelerate to inform timing of intervention. METHODS Adult (≥ 18 years old) patients with sporadic vestibular schwannoma who underwent SRS from 2000 through 2022 were included. RESULTS A total of 749 patients with a median age at SRS of 62 years were studied, the majority (n = 566 [76%]) of whom had tumors extending into the cerebellopontine angle (CPA) at SRS. The optimal tumor size cut point to predict SRS failure and need for salvage treatment was 4 mm or more of CPA extension (c-index 0.59, HR 3.60, p = 0.01). The optimal tumor size cut point to predict the outcome of facial nerve paresis was 13 mm or more of CPA extension, resulting in a c-index of 0.63 (HR 2.88, p = 0.01). Among patients with at least 3 months of surveillance before SRS, those with a tumor growth rate ≥ 2.5 mm/year were more likely to undergo salvage treatment than those with a growth rate < 2.5 mm/year, although this difference did not achieve statistical significance (HR 1.82, p = 0.18). CONCLUSIONS The risk of SRS failure requiring salvage treatment and the risk of post-SRS facial nerve paralysis increase at sizes of approximately 4 and 13 mm extension into the CPA, respectively, providing a size threshold anchor to help guide treatment decision-making regarding timing of SRS. Furthermore, rapid tumor growth during the initial wait-and-scan period may be associated with an increased risk of radiosurgical failure, which may influence choice of treatment.
Four-lead deep brain stimulation for multifocal drug-resistant epilepsy: surgical safety profile and preliminary effectiveness
Peters, Pierce A., Zhou, Roy , Singh, Raunak, Gregg, Nick M., Worrell, Gregory, Miller, Kai J. , Gompel, Jamie J. Van, Singh, Raunak , Gregg, Nick, Worrell, Gregory A. , Lundstrom, Brian N. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 4 | Pages: 767-778

10.3171/2025.8.jns251288 | PMID 41569668 Get It

OBJECTIVE Deep brain stimulation (DBS) is emerging as an additional surgical option for refractory, multifocal epilepsy. Four-lead DBS systems can be used when seizure onset is poorly localized, generalized, or involves multiple targetable circuits. The goal of this study was to assess preliminary outcomes and complication rates in 4-lead DBS systems for treating epilepsy. METHODS A consecutive series of 32 patients with 4-lead DBS implants who had at least 6 months of follow-up was reviewed, and demographics, outcomes, and complications were abstracted. RESULTS Thirty-two patients implanted with 4 DBS leads (including off-label use) were included. The median age at surgery was 28.5 years, the median age at epilepsy diagnosis was 7.5 years, and 18 patients (56%) were women. The median epilepsy duration prior to implantation was 21 years. The most common seizure localization was frontotemporal (53%), followed by generalized (28%) and parietoccipital (13%). Prior vagus nerve stimulation had been trialed in 20 patients (63%), and an invasive stereotactic EEG recording was performed in 17 patients (59%). Eight patients had prior epilepsy surgery (25%). DBS targets included the anterior thalamic nucleus in combination with the centromedian thalamic nucleus, hippocampus, pulvinar nucleus, cingulate, insula, and globus pallidus. The median surgical duration was 5 hours 22 minutes, with a median operating room time of 8 hours 21 minutes. The median postoperative follow-up was 27 (interquartile range 17–41) months. Three patients experienced transient neurological deficits and 2 patients required intraoperative lead repositioning. There were no infections or hemorrhages. Most patients benefited from stimulation (22% Engel class I, 22% class II, 28% class III, and 28% class IV). The median patient-reported seizure reduction rate was 70%, with a responder rate of 72%. One patient elected to have the system explanted. CONCLUSIONS Four-lead DBS is safe and can achieve meaningful improvement in challenging cases of multifocal epilepsy with a low complication rate.
mRNA Therapy for Alport Syndrome
Parrett, Brian J. , Barry, Michael A.

Mayo Clinic

No container title available | January 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.20.700554 | PMID 41648584 Get It

Abstract Alport syndrome is caused by mutations in the type IV collagen genes COL4A3, COL4A4, and COL4A5 which are expressed in podocytes in the glomerulus of the kidney. Mutation of these genes disrupts blood filtration by the kidney leading to proteinuria and kidney failure. There is no cure for Alport Syndrome. Current therapies do not treat the genetic cause of the disease, but instead aim to delay the disease by reducing blood pressure in the kidney. Here we tested the ability of mRNA therapy to treat the disease. Mice with X-linked Alport syndrome (XLAS) due to mutation of Col4A5 were treated intravenously with lipid nanoparticles (LNPs) carrying three mRNAs encoding COL4A3, COL4A4, and COL4A5 to produce trimeric collagen IV repair proteins. This intravenous mRNA therapy significantly reduced proteinuria and blood urea nitrogen. Protection against the syndrome was maintained provided that LNP-mRNA injections were continued. However, efficacy was lost when therapy was terminated. These data provide proof of principle to apply a genetic mRNA therapy to halt progression of Alport syndrome in a mouse model of XLAS. These data also demonstrate that damage to the kidney filtration barrier can be leveraged to deliver large molecular therapies to podocytes and other cells within the kidney to treat Alport syndrome and other kidney genetic diseases.
Setting the Standard in Robotic Whipple Surgery
Pfister, Matthias , Li, Zhihao, Araujo, Raphael L. C., Chaudhari, V., Chérif, Rim , Foroutani, Laleh , Ginesini, Michael, Iben-Khayat, Abdallah , Lee, Boram, Nunez, Ricardo, Takishita, Chie, Vigia, Emanuel , Watanabe, Yusuke , Wakabayashi, Taiga , Alseidi, A., Benedetto, Fabrizio Di, Boggi, Ugo, Brustia, Dr Raffaele, Cheung, Tan-To, Dillhoff, Mary E., Goh, BrianK P, Han, Ho-Seong, Ielpo, Benedetto, Lee, Jae Hoon, Machado, Marcel A., Marques, Hugo Pinto, Mejia, Alejandro, Nakamura, Masafumi, Pessaux, Patrick, Polanco, Patricio M., Saint-Marc, Olivier, Shrikhande, S., Wakabayashi, Go, Clavien, Pierre-Alain, Marques, Hugo P. , Li, Zhihao , Ielpo, Benedetto , Clavien, Pierre-Alain , Li, Zhihao , Abbassi, Fariba , Cherif, Rim, Giannone, Fabio , Ginesini, Michael , Underwood, Patrick W. , Vivian, Elaina , Benedetto, Fabrizio Di , Boggi, Ugo , Brustia, Raffaele , Dillhoff, Mary , Goh, Brian K P , Han, Ho-Seong , Lee, Jae Hoon , Martinie, John B. , Mejia, Alejandro , Nagakawa, Yuichi , Nakamura, Masafumi , Pessaux, Patrick , Polanco, Patricio Marcelo , Saint‐Marc, Olivier , Shrikhande, S., Wakabayashi, Go , Clavien, Pierre‐Alain

Mayo Clinic

Annals of Surgery | January 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000007014 | PMID 41562520 Get It

Objective: To establish international benchmark values for relevant outcome parameters in robotic Whipple. Summary Background Data: For safe adoption of surgical innovation, robust quality control is essential. Benchmarking is a validated tool for assessing surgical performance. Recent international consensus identified establishing benchmark values for robotic Whipple as top priority. Methods: We analyzed consecutive patients undergoing robotic Whipple between 2020-2023 with a minimum one-year follow-up. Reference centers were required to perform ≥15 cases/year, be scientifically active in the field, and maintain a prospective database. Benchmark criteria included benign or resectable malignant disease without neoadjuvant therapy, arterial resection, major co-morbidities, or significant previous abdominal surgery. Benchmarks were established for 13 outcome parameters. Result: The benchmark cohort comprised 418 patients from 12 centers across four continents. Benchmark values were: conversion rate ≤4.3%, transfusion rate ≤2.1%, 6-month mortality ≤2.2%, major complications ≤23.2%, and CCI® ≤20.9. Clinically relevant pancreatic fistula (grade B/C) and hemorrhage (grade B/C) rates were ≤23.6% and ≤12.7%, respectively. For pancreatic ductal adenocarcinoma (n=123), the benchmark for lymph node yield was ≥20. Higher surgical difficulty was associated with increased overall postoperative morbidity (R 2 =0.38, P =0.019), higher center caseload with reduced pancreas-specific complications (R 2 =0.28, P =0.044). Independent POPF predictors included duct diameter ≤4 mm (OR 1.37, 95% CI: 1.03, 1.82), anticoagulation (OR 2.45, 95% CI: 1.47, 3.99), and indication other than PDAC (OR 2.33, 95% CI: 1.68, 3.27). Conclusions: This study establishes the first international benchmarks for robotic Whipple, demonstrating oncologic outcomes and morbidity comparable to open surgery with the benefits of minimally invasive surgery.